Back pain: empirical and personalized approach to drug therapy. Conclusion of the Expert Council of the Russian Society for the Study of Pain

Objective. To present the recommendations of the expert council of the Russian Society for the Study of Pain on “Dorsumio” drug in the treatment of chronic nonspecific back pain (CNBP). Key points. Currently, CNBP is the leading disease associated with disability worldwide. Patients with CNBP often experience concomitant depressive and anxiety symptoms complicating the course of disease and therapy, as well as worsening the quality of life and working capacity. Various problems in care for CNBP include not only the impact on pathogenesis of chronic pain, but also treatment of depression, anxiety, insomnia, assessment of compatibility of various drugs and patient adherence to therapy. The new drug “Dorsumio” (mirtazapine 15 mg + tizanidine 6 mg) can influence on chronic pain mechanisms and provide effective therapy for patients with chronic nonspecific back pain due to complex analgesic, muscle relaxant, antidepressant and anti-anxiety effects. © 2025 Elsevier B.V., All rights reserved.